BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38050741)

  • 1. Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.
    Catalano M; Lavacchi D; Giommoni E; Shabani S; Guidolin A; Brugia M; Petrioli R; Ramello M; Pillozzi S; Antonuzzo L; Roviello G
    Future Oncol; 2023 Dec; 19(38):2537-2546. PubMed ID: 38050741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
    Jo H; Lee MS; Lee YP; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):e323-e328. PubMed ID: 35248464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
    Chau I; Joulain F; Iqbal SU; Bridgewater J
    BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
    Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
    Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
    Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
    Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
    Raga MG; Pérez IP; Veiga RC; Sosa MM; Aguilera MJS; Rodríguez PL; Bonastre MTT; Urtasun JA; Abad LP; Hernández IB
    Clin Transl Oncol; 2023 May; 25(5):1455-1462. PubMed ID: 36723787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
    Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
    Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
    Joulain F; Proskorovsky I; Allegra C; Tabernero J; Hoyle M; Iqbal SU; Van Cutsem E
    Br J Cancer; 2013 Oct; 109(7):1735-43. PubMed ID: 24045663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
    Piringer G; Thaler J; Anchisi S; Geffriaud-Ricouard C; Gueldner M; Scholten F; Derigs HG; Bohanes P; Grünberger B; Schwarz L; von Moos R; Hofheinz RD
    J Geriatr Oncol; 2023 Nov; 14(8):101638. PubMed ID: 37776611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
    Pericay C; Frías C; Abad A; Lamas MJ; Echave M; Oyagüez I; Rubio M; Giménez E; Naoshy S; Joulain F
    Farm Hosp; 2014 Jul; 38(4):317-27. PubMed ID: 25137165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
    Élez E; Gómez-España MA; Grávalos C; García-Alfonso P; Ortiz-Morales MJ; Losa F; Díaz IA; Graña B; Toledano-Fonseca M; Valladares-Ayerbes M; Polo E; Salgado M; Martínez de Castro E; Safont MJ; Salud A; Ruiz-Casado A; Tabernero J; Riesco MDC; Rodriguez-Ariza A; Aranda E
    Br J Cancer; 2022 Apr; 126(6):874-880. PubMed ID: 34937947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
    Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
    Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
    Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
    Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
    Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
    Toledano-Fonseca M; Gómez-España MA; Élez E; Grávalos C; García-Alfonso P; Rodríguez R; Losa F; Alés Díaz I; Graña B; Valladares-Ayerbes M; García-Ortiz MV; Polo E; Salgado M; Rivera F; Safont MJ; Salud A; Ruiz-Casado A; Tabernero JM; Riesco MC; Rodríguez-Ariza A; Aranda E;
    Biomed Pharmacother; 2023 Mar; 159():114272. PubMed ID: 36706629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
    Li J; Xu R; Qin S; Liu T; Pan H; Xu J; Bi F; Lim R; Zhang S; Ba Y; Bai Y; Fan N; Tsuji A; Yeh KH; Ma B; Wei V; Shi D; Magherini E; Shen L
    Future Oncol; 2018 Aug; 14(20):2031-2044. PubMed ID: 30117334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.